Regen BioPharma, Inc. (RGBP)
OTCMKTS · Delayed Price · Currency is USD
0.0007
+0.0001 (16.67%)
Apr 15, 2026, 3:58 PM EST
Regen BioPharma Revenue
Regen BioPharma had revenue of $59.07K in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to $236.56K. In the fiscal year ending September 30, 2025, Regen BioPharma had annual revenue of $236.56K.
Revenue
236.56K
Revenue Growth
n/a
P/S Ratio
1.04
Revenue / Employee
236.56K
Employees
1
Market Cap
246.01K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 236.56K | 1.00 | - |
| Sep 30, 2024 | 236.56K | - | - |
| Sep 30, 2023 | 236.56K | 1.04K | 0.44% |
| Sep 30, 2022 | 235.52K | 64.32K | 37.57% |
| Sep 30, 2021 | 171.19K | 61.19K | 55.63% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regenerative Medical Technology Group | 5.04M |
| Helix BioMedix | 2.07M |
| Lipella Pharmaceuticals | 389.78K |
| GB Sciences | 97.24K |
| CNBX Pharmaceuticals | 40.64K |
| THC Farmaceuticals | 18.52K |
Regen BioPharma News
- 5 months ago - Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. - Accesswire
- 1 year ago - Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ - GlobeNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time - GlobeNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024 - PRNewsWire